Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

TechCrunch Senior Reporter Rebecca Bellan breaks down Elon Musk’s latest move to bring Grok AI to Tesla vehicles and why the ...

Genmab A/S Sponsored ADR (GMAB) closed the last trading session at $21.69, gaining 4.9% over the past four weeks, but there ...

AXT Inc (AXTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...